|Assessment Status||Rapid review complete|
|Indication||For the treatment of chronic kidney disease|
|Rapid review commissioned||08/06/2022|
|Rapid review completed||14/07/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that dapaglifozin not be considered for reimbursement at the submitted price.*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.